摘要
目的对比研究^89SrCl2和^153Sm-乙二胺四亚甲基膦酸（^153Sm-EDTMP）治疗骨转移癌疗效。方法120例骨转移患者随机分为SOSrCl2治疗组和^153Sm-EDTMP治疗组，分别为69例和51例，^89SrCl2剂量为1．11-2．22MBq／kg，^153Sm-EDTMP剂量为25．9～37．0MBq／kg，3-6月复查SPECT，对止痛效果、转移灶变化及不良反应进行比较分析。结果^89SrCl2组总有效率、显效、有效、无效分别为92．8％、69．6％、23．3％、7．2％；^153Sm-EDTMP组的总有效率、显效、有效、无效分别为94．2％、66．7％、27．5％、5．8％，两组比较的差异无统计学意义（χ^2=4．98，P〉0．05）；^89SrCl2治疗组骨转移病灶Ⅰ级（变淡，缩小或消失，无新增病灶出现）为56．5％，^153Sm-EDTMP组为54．9％，两组比较的差异无统计学意义（χ^2=4．81，P〉0．05）；骨髓抑制情况（白细胞和血小板中任一项降低）分别为40．8％和59．2％，两组比较的差异有统计学意义（r=7．45，P〈0．05）。结论^153sm-EDTMP和^89SrCl2控制乳腺癌、前列腺癌及大多数肺癌骨转移疼痛有效，可根据经济条件选择相应药物。^89SrCl2疗效持久，相对骨髓抑制较小，更安全可靠，可作为早期骨转移患者的首选药物。
Objective To evaluate the effect of ^89SrCl2 and ^153Sm-ethylenediaminetetramethylene phosphonate （^153Sm-EDTMP） on metastatic carcinoma of bone. Methods All patients with widespread metastatic bone cancers were divided into two groups randomly： sixty-nine patients were treated with ^89SrCl2 with dose of 1.11-2.22 MBq/kg by intravenous injection, fifth-one patients were treated with 153Sm-EDTMP with dose of 25.9 -37.0 MBq/kg by the same way. Bone imaging was analized in 3 -6 months. The pain, the metastasis varied situation, and side-effect were compared. Results In the group of ^89SRCl2 the remission rats of bone pain of positive response, total-effect, apparent, finess, no-effect was 92.8%, 69.6%, 23.3%, 7.2% respectively. In the group of ^153Sm-EDTMP, the data were 94.2%, 66.7%, 27.5%, 5.8% respectively. There were not significantly different between groups of ^89SrCl2 and ^153Sm-EDTMP （χ^2=4.98, P〉0. 05）. In group of ^89SrCl2 the rate of area of skeletal metastases Grade I （disappear, reduction, maintain and no-new- development） was 56.5%. However it was, in ^153Sm-EDTMP group, 54.9%. There was no significantly difference between ^89SrCl2 and 153Sm-EDTMP groups （χ^2=4.81, P〉0.05）. The arrest rate of bone marrow （white blood or blood platelet was descended） of 89SRCl2 group was 40.8% while in ^153Sm-EDTMP group was 59.2%. There was a significantly different between them （χ^2=7.45, P〈0.05）. Conclusion ^89SrCl2 and ^153Sm- EDTMP have effeet on metastatic carcinoma of bone treatment. It is suggested that one can choose each of them by economic condition. But, ^89SrCl2 can maintain the effect in a long time and bone marrow is arrested serious, so it is the first ehoise for early metastatic carcinoma of bone.
出处
《国际放射医学核医学杂志》
2009年第2期86-88,共3页
International Journal of Radiation Medicine and Nuclear Medicine
关键词
肿瘤转移
骨肿瘤
锶放射性同位素
^153Sm-乙二胺四亚甲基膦酸
Neoplasm metastasis
Bone neoplasms
Strontium radioisotopes
153Sm-ethylene diamihe tetramethylene phosphonic acid
